Tobacco Boosts In-Store Advertising

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

WASHINGTON-Tobacco companies, which were banned from touting their products on billboards last year, have increased their advertising at point-of-sale locations, such as convenience stores, according to a new study funded by the Robert Wood Johnson Foundation.

WASHINGTON—Tobacco companies, which were banned from touting their products on billboards last year, have increased their advertising at point-of-sale locations, such as convenience stores, according to a new study funded by the Robert Wood Johnson Foundation.

In-store advertising was present in 80% of the stores visited, an increase of 27% over the display ads present prior to the billboard ban. Exterior advertising was observed at 60% of the stores, an increase of 22%. Tobacco promotions were available at 52% of stores visited after the ban, an increase of 65%.

“The shift in advertising expenditure is likely to mean that any intended effect of the billboard advertising ban—as well as other advertising restrictions—will not be fully realized,” said lead researcher Frank Chaloupka, PhD, of the University of Illinois at Chicago.

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.